This is the
talk page for discussing improvements to the
Escitalopram article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives:
1,
2Auto-archiving period: 90 days
![]() |
![]() | This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Escitalopram.
|
![]() | This page is not a forum for general discussion about Escitalopram. Any such comments may be removed or refactored. Please limit discussion to improvement of this article. You may wish to ask factual questions about Escitalopram at the Reference desk. |
![]() | The contents of the List of adverse effects of escitalopram page were merged into Escitalopram on 9 August 2020. For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. |
This page has archives. Sections older than 90 days may be automatically archived by Lowercase sigmabot III when more than 6 sections are present. |
Could we get some information/studies/details on how escitalopram and alcohol might interact, and whether they do in fact interact at all? — Preceding unsigned comment added by 184.45.25.61 ( talk) 18:57, 16 March 2017 (UTC)
I am concerned that the use of the word "controversial" in second sentence of this article is unwarranted.
If you read the 2010 meta-analysis cited here, it doesn't look at Escitalopram, but rather at (only) 3 studies of one older SSRI, paroxetine, and three studies of the tricycle (TCA), imipramine, an old kind of antidepressant medication (ADM) that is hardly used anymore. The JAMA article also mentions several studies of ADM for dysthymia (a less severe, but chronic, depression), that show ADM demonstrates a “true” drug effect in patients with mild or moderate depressive symptoms.
It is my opinion that if scientific doubt about the efficacy of any particular SSRI were to be mentioned, it might be better phrased with less arousing language, such as is used in the third paragraph of the Selective serotonin reuptake inhibitor article:
There are plenty of good articles expressing doubts and worries about the explosion of use of SSRIs, such as Percentage of Americans on Antidepressants Nearly Doubles, 6Nov2015. But one in three adults will experience an episode of Major Depressive Disorder (MDD), so IMO, it'd be better just to omit this whole sentence from the article, than leave it there as is, like a little IED that sows doubt in the mind of some poor soul struggling to take the advice of their medical professional.
For convenience, here are the two relevant sections of the JAMA meta-analysis [1] that I referred to:
[...] Three studies utilized the tricyclic antidepressant (TCA) imipramine and three utilized the selective serotonin reuptake inhibitor (SSRI) paroxetine. [...] The pooled sample used in the current analyses included 434 patients in the ADM group and 284 patients in the placebo group.
[...] Several studies have demonstrated that ADM is superior to placebo for patients diagnosed with dysthymia, a condition partly defined by lower symptom levels relative to MDD. The dysthymia studies indicate that ADM can produce a “true” drug effect in patients with mild or moderate depressive symptoms. However, dysthymia is by definition a chronic condition, and chronicity is known to be associated with poor response to placebo.
Cite error: A
list-defined reference with the name "Fou2010" has been invoked, but is not defined in the <references>
tag (see the
help page).
Cite error: A
list-defined reference with the name "JAMA2010" has been invoked, but is not defined in the <references>
tag (see the
help page).
Cite error: A
list-defined reference with the name "Kramer" has been invoked, but is not defined in the <references>
tag (see the
help page).
Cite error: A
list-defined reference with the name "Pies" has been invoked, but is not defined in the <references>
tag (see the
help page).
Permacultura ( talk) 03:29, 9 March 2017 (UTC)
Hello fellow Wikipedians,
I have just modified one external link on Escitalopram. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 02:30, 9 December 2017 (UTC)
![]() | This edit request by an editor with a conflict of interest was declined. |
·Information to be added: Suicide/suicidal thoughts or clinical worsening.
Edit request
|
---|
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical studies of antidepressants in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo, in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted to the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. ·Explanation of issue: At the top of the page, there is a mention to serious side effects related to suicide ("More serious side effects may include suicide in people under the age of 25"). This mention is a section of the SmPC and miss essential information related to Suicide/suicidal thoughts clinical worsening. It is important to include the full class label related to the SmPC as stated above with the below reference. ·References supporting change: Cite error: There are |
AudreyDufour ( talk) 10:17, 5 February 2020 (UTC)
Regards, Spintendo 20:27, 5 February 2020 (UTC)
The chemistry section appears to be incomplete. 67.163.170.208 ( talk) 10:00, 9 August 2023 (UTC)
Anybody knows who is a manufacturer? Irochka1428 ( talk) 17:21, 19 October 2023 (UTC)